iolat
27 Jul 2017
Chemotherapy Chemotherapy not apparently not a very pleasant procedure but very necessary, if these new drugs can achieve the same results without undergoing the same procedure then surely it would be first choice depending on costs.
LK Hyman
27 Jul 2017
Re: Down 15% at 08
9 Our Haven,"not tempted to buy back in?"No, not tempted to buy back in, m8. I know very little about tabs (other than aspirin) but my impression is that most of the tabs out there have already been discovered and that the cost of finding new 'uns, even if one has a gold-plated pipette and a white coat double-washed in ULVR's Persil, ain't barely worth the candle any more. So I shall be staying out ... assisted by the fact that my IHT planning exercise means that I don't got the moolah any more even if I WANTED to buy back in ... which I don't.It's Woody I feel sorry for. The crop-haired thug has been bigging up on Sorry Hat's baby, which he has regularly praised to the skies, so he must be feeling like the chubby boy as well today.LKH on the flybridge tucks crossbow back into its sheath
Jack_Walsh
27 Jul 2017
Re: Down 15% at 089 I added another 50% this morning at £43.20, as the recent 20% call from soriot rumours and failed mystic trial looks a little harsh.5% div provides insulation in the meanwhile.As likely to end the day at -20% as -10%; although, not looking too clever atm.
Our Haven
27 Jul 2017
Re: Down 15% at 089 LKH. Squealing chubby boy here, not tempted to buy back in?
LK Hyman
27 Jul 2017
Re: Down 15% at 089 Games,I wonder if them Israeli top boys will want Sorry Hat now?pure joss I sold all my AZN shares at the beginning of this week as part of an IHT planning exercise so managed to miss this disaster, otherwise I would be squealing like the chubby boy in Deliverance after his encounter with the mountain men.LKH on the flybridge
Simbrad
31 May 2016
Beaufort's note published this morning is up on Research Tree... The aforementioned updates are mixed for AstraZeneca. The successful trial of Faslodex 500mg offers earlier treatment options to post-menopausal women with HR+ locally advanced or metastatic breast cancer. The drug has more than 10 years of clinical evidence and was recently approved by FDA for use in combination with palbociclib in the treatment of women with hormone-receptor-positive, humanepidermal-growth-factor-receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC). On the other hand, disapproval of AstraZeneca's new drug (ZS-9) for high potassium levels due to a manufacturing issue is a major setback. AstraZeneca paid US$2.7bn for ZS Pharma to gain access to the drug. Moreover, many of its drugs are in the development phase. AstraZeneca has been facing certain growth-related issues, as some of its key drugs are approaching patent expiry.
Simbrad
24 May 2016
AlphaValue's published a note on AstraZeneca, out this morning on Research Tree: "AstraZeneca’s Q1 results came in behind our expectations with product sales growth of 1% to $5.6bn. Externalisation revenue (+78%) contributed $550m, leading to group sales of $6.1bn (+5%). NB All growth numbers at CER unless specific otherwise. Currency had a negative impact of 4% on group sales, which ended at 1% growth yoy. Higher-than-expected R&D spend (+11%) was offset to some extent by effective cost containment at COGS (-19%) and SG&A (-8%), culminating in reported operating profit of $1bn (+17%). Core operating..."
